Patents by Inventor Scott D. Bembenek

Scott D. Bembenek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE
    Publication number: 20230097422
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Application
    Filed: March 25, 2022
    Publication date: March 30, 2023
    Inventors: Nidhi ARORA, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J.M. Wiener
  • Inhibitors of Bruton's tyrosine kinase and methods of their use
    Patent number: 11319329
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: May 3, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener
  • INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE
    Publication number: 20210101910
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Application
    Filed: May 13, 2020
    Publication date: April 8, 2021
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J.M. Wiener
  • Inhibitors of Bruton's tyrosine kinase and method of their use
    Patent number: 10934310
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: March 2, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener, Yao Wu, Kun Xiao, Feihuang Zhang, Yaoping Zhu
  • Inhibitors of Bruton's tyrosine kinase and methods of their use
    Patent number: 10822348
    Abstract: The present disclosure is directed to compounds of formula I? and methods of their use and preparation, as well as compositions comprising compounds of formula I?.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: November 3, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Baoyu Hao, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener, Yao Wu, Yaoping Zhu, Feihuang Zhang, Zheng Zhang, Kun Xiao
  • Inhibitors of Bruton's tyrosine kinase and method of their use
    Patent number: 10800792
    Abstract: The present disclosure is directed to compounds of formula I? and methods of their use and preparation, as well as compositions comprising compounds of formula I?.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: October 13, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Baoyu Hao, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener, Yao Wu, Yaoping Zhu, Feihuang Zhang, Zheng Zhang, Kun Xiao
  • Inhibitors of Bruton's tyrosine kinase and method of their use
    Patent number: 10717745
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 21, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener, Yao Wu, Kun Xiao, Feihuang Zhang, Yaoping Zhu
  • Inhibitors of Bruton's tyrosine kinase and methods of their use
    Patent number: 10689396
    Abstract: The present disclosure is directed to compounds of formula I? and methods of their use and preparation, as well as compositions comprising compounds of formula I?.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: June 23, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Baoyu Hao, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener, Yao Wu, Yaoping Zhu, Feihuang Zhang, Zheng Zhang, Kun Xiao
  • INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE
    Publication number: 20190284203
    Abstract: The present disclosure is directed to compounds of formula I? and methods of their use and preparation, as well as compositions comprising compounds of formula I?.
    Type: Application
    Filed: May 15, 2019
    Publication date: September 19, 2019
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Baoyu Hao, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J.M. Wiener, Yao Wu, Yaoping Zhu, Feihuang Zhang, Zheng Zhang, Kun Xiao
  • INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE
    Publication number: 20190284204
    Abstract: The present disclosure is directed to compounds of formula I? and methods of their use and preparation, as well as compositions comprising compounds of formula I?.
    Type: Application
    Filed: May 15, 2019
    Publication date: September 19, 2019
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Baoyu Hao, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J.M. Wiener, Yao Wu, Yaoping Zhu, Feihuang Zhang, Zheng Zhang, Kun Xiao
  • INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE
    Publication number: 20190276471
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Application
    Filed: May 15, 2019
    Publication date: September 12, 2019
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J.M. Wiener, Yao Wu, Kun Xiao, Feihuang Zhang, Yaoping Zhu
  • INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE
    Publication number: 20170283430
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Application
    Filed: December 9, 2016
    Publication date: October 5, 2017
    Inventors: Nidhi ARORA, Genesis M. BACANI, Joseph Kent BARBAY, Scott D. BEMBENEK, Min CAI, Wei CHEN, Charlotte Pooley DECKHUT, James P. EDWARDS, Brahmananda GHOSH, Kevin D. KREUTTER, Gang LI, Mark S. TICHENOR, Jennifer D. VENABLE, Jianmei WEI, John J.M. WIENER, Yao WU, Kun XIAO, Feihuang ZHANG, Yaoping ZHU
  • INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE
    Publication number: 20170283431
    Abstract: The present disclosure is directed to compounds of formula I? and methods of their use and preparation, as well as compositions comprising compounds of formula I?.
    Type: Application
    Filed: December 9, 2016
    Publication date: October 5, 2017
    Inventors: Nidhi ARORA, Genesis M. BACANI, Joseph Kent BARBAY, Scott D. BEMBENEK, Min CAI, Wei CHEN, Charlotte Pooley DECKHUT, James P. EDWARDS, Brahmananda GHOSH, Baoyu HAO, Kevin D. KREUTTER, Gang LI, Mark S. TICHENOR, Jennifer D. VENABLE, Jianmei WEI, John J.M. WIENER, Yao WU, Yaoping ZHU, Feihuang ZHANG, Zheng ZHANG, Kun XIAO
  • Quinazolinones as prolyl hydroxylase inhibitors
    Patent number: 8937078
    Abstract: Quinazolinone compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.
    Type: Grant
    Filed: February 10, 2010
    Date of Patent: January 20, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Scott D. Bembenek, Frances M. Hocutt, Barry Eastman Leonard, Jr., Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan
  • Aryl-substituted bridged or fused diamines as modulators of leukotriene Ahydrolase
    Patent number: 8367719
    Abstract: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: February 5, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Genesis M. Bacani, Scott D. Bembenek, Wendy Eccles, James P. Edwards, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Kelly J. McClure, Taraneh Mirzadegan, Alejandro Santillán, Jr.
  • Aryl-substituted bridged or fused diamines as modulators of leukotriene A ydrolase
    Patent number: 8344008
    Abstract: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: January 1, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Genesis M. Bacani, Scott D. Bembenek, Wendy Eccles, James P. Edwards, Matthew T. Epperson, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Kelly J. McClure, Taraneh Mirzadegan, Alexandro Santillán, Jr.
  • Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
    Publication number: 20110263639
    Abstract: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
    Type: Application
    Filed: April 21, 2011
    Publication date: October 27, 2011
    Inventors: Genesis M. Bacani, Scott D. Bembenek, Wendy Eccles, James P. Edwards, Matthew T. Epperson, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Kelly J. McClure, Taraneh Mirzadegan, Alejandro Santillán, JR.
  • Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
    Publication number: 20110257153
    Abstract: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
    Type: Application
    Filed: April 21, 2011
    Publication date: October 20, 2011
    Inventors: Genesis M. Bacani, Scott D. Bembenek, Wendy Eccles, James P. Edwards, Matthew T. Epperson, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Kelly J. Mcclure, Taraneh Mirzadegan, Alexandro Santillan, JR.
  • Aryl-substituted bridged or fused diamines as modulators of leukotriene Ahydrolase
    Patent number: 7935725
    Abstract: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: May 3, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Scott D. Bembenek, Wendy Eccles, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Taraneh Mirzadegan, Alejandro Santillán, Jr.
  • QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20100204226
    Abstract: Quinazolinone compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.
    Type: Application
    Filed: February 10, 2010
    Publication date: August 12, 2010
    Inventors: Scott D. Bembenek, Frances M. Hocutt, Barry Eastman Leonard, JR., Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan